ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2020
Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01468246 (Helping Ourselves, Helping Others), which is not on this map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Helping Ourselves, Helping Others: The Young Women's Breast Cancer Study
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review and economic evaluation.Health technology assessment (Winchester, England) · 2025Pooled it
- Gene expression profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review.Breast cancer research and treatment · 2025Pooled it
- 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.The New England journal of medicine · 2021Trial
- Development and validation of a nomogram to assess recurrence risk in young patients with breast cancer based on preoperative serum tumor markers.Gland surgery · 2026Article
- Extended Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients.JAMA network open · 2026Article
- Personalized survival prediction in young Asian American breast cancer.Gland surgery · 2026Article
- Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer.Nature reviews. Clinical oncology · 2026Review
- Tumour microbiota activities associated with local recurrence in ER + PR + breast cancer.Cancer biomarkers : section A of Disease markers · 2025Article
- Nomograms to predict the long-term prognosis for non-metastatic invasive lobular breast carcinoma: a population-based study.Scientific reports · 2024Article
- Article
- Research progress on the structure, function, and use of angiogenin in malignant tumours.Heliyon · 2024Review
- Identification of a PANoptosis-related Gene Signature for Predicting the Prognosis, Tumor Microenvironment and Therapy Response in Breast Cancer.Journal of Cancer · 2024Article
- Young Women with Breast Cancer: The Current Role of Precision Oncology.Journal of personalized medicine · 2023Review
- Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study.Cancers · 2022Article
- The functional roles of the circRNA/Wnt axis in cancer.Molecular cancer · 2022Review
- Article
- Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer.British journal of cancer · 2022Article
- The Utility of the Oncotype DX Test for Breast Cancer Patients in an Australian Multidisciplinary Setting.The breast journal · 2022Article
- A Novel Inflammatory-Nutritional Prognostic Scoring System for Patients with Early-Stage Breast Cancer.Journal of inflammation research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 9 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe 21-gene recurrence score (RS) assay is prognostic among women with early-stage estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer and is used to inform recommendations for chemotherapy. Women ≤ 40 years of age represent a minority of patients studied using gene expression profiles.
methodsThe Young Women's Breast Cancer Study is a prospective cohort of women diagnosed with breast cancer at age ≤ 40 years and enrolled patients between 2006 and 2016 (N = 1,302). We identified patients with stage I-III ER+/HER2- breast cancer. The RS assay was performed on banked specimens for patients who had not been tested clinically. Distant recurrence-free survival (DRFS) was assessed by TAILORx and traditional RS risk groups among patients with axillary node-negative (N0) and limited node-positive (N1) breast cancer.
resultsAmong eligible women (N = 577), 189 (33%) had undergone RS testing, and 320 (56%) had banked specimens sufficient for testing. Median follow-up was 6.0 years. Median age at diagnosis was 37.2 years; 300 of 509 patients (59%) had N0 breast cancer, of whom 195 (65%) had an RS of 11-25 and fewer than half (86 of 195; 44%) received chemotherapy. Six-year DRFS rates were 94.4% and 92.3% (RS < 11), 96.9% and 85.2% (RS 11-25), and 85.1% and 71.3% (RS ≥ 26) among women with N0 and N1 disease, respectively.
conclusionThe RS assay is prognostic among young women with node-negative and limited node-positive breast cancer, representing a valuable tool for risk stratification. Disease outcomes with a median follow-up of 6 years among young women with N0 disease and an RS of 0-25, a minority of whom received chemotherapy, and node-positive disease with an RS < 11 were very good, whereas those with N0 disease and an RS ≥ 26 or N1 disease with an RS ≥ 11 experienced substantial risk of early distant recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.